U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07108036) titled 'A Study to Assess Anktiva in Patients With Long Covid-19.' on July 30.
Brief Summary: This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Long COVID
Intervention:
DRUG: N-803 (IL-15 Superagonist)
N-803 administered subcutaneously.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: ImmunityBio, Inc.
Disclaimer: Curated by HT Syndication....